Key result
Patients with TIA had no significant differences in platelet findings versus controls, while antiplatelet therapy decreased circulating platelet aggregates and inhibited secondary aggregation.
Why the study?
Do anticoagulants or antiplatelet drugs alter circulating platelet aggregates and induced platelet aggregation in patients with transient ischemic attacks?
Observational (n=67)
Do anticoagulants or antiplatelet drugs alter circulating platelet aggregates and induced platelet aggregation in patients with transient ischemic attacks?
Antiplatelet effects on aggregates may guide monitoring in TIA; in vitro Level 5 data leave open clinical outcome links.
Routine blood analysis, platelet counts, number of circulating platelet aggregates (CPA) and platelet aggregation in vitro against adenosine-diphosphate (ADP), epinephrine and collagene were studied in 45 healthy controls, in 10 hospitalized patients with other neurological diseases than stroke and in 12 patients with transient ischemic attacks (TIA) before and after prophylactive treatment with anticoagulants (AC) or antiplatelet drugs (APD). Except for lower hemoglobin and hematocrit levels in women, sex, smoking, oral contraceptives of pregnancy did not significantly influence the routine blood parameter. Smoking females taking oral contraceptive had an increased number of CPA and the most easily induced aggregation in vitro. Patients with TIA had no significant differences in blood or platelet findings versus the healthy controls (except smoking females on oral contraceptives) or the non-stroke patients, even though individual patients could have high numbers of CPA and an easily induced platelet aggregation in vitro. Treatment with AC did not influence platelet function, whereas APD therapy decreased the number of CPA and inhibited the secondary platelet aggregation in vitro.
No takes yet. Share an insight, caveat, or question.
Jan‐Edvin Olsson (2009) conducted an observational in Transient ischemic attacks (TIA) (n=67). Anticoagulants (AC) or antiplatelet drugs (APD) vs. Before treatment / healthy controls was evaluated on Routine blood analysis, platelet counts, number of circulating platelet aggregates (CPA) and platelet aggregation in vitro. Patients with TIA had no significant differences in platelet findings versus controls, while antiplatelet therapy decreased circulating platelet aggregates and inhibited secondary aggregation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: